MA32557B1 - Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire - Google Patents

Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire

Info

Publication number
MA32557B1
MA32557B1 MA33608A MA33608A MA32557B1 MA 32557 B1 MA32557 B1 MA 32557B1 MA 33608 A MA33608 A MA 33608A MA 33608 A MA33608 A MA 33608A MA 32557 B1 MA32557 B1 MA 32557B1
Authority
MA
Morocco
Prior art keywords
sphingosine
modulators
treatment
muscle inflammation
phosphate receptor
Prior art date
Application number
MA33608A
Other languages
Arabic (ar)
English (en)
Inventor
Syed Sohail Ahmed
Marco Londei
Timothy Wright
Peter Gergely
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32557(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32557B1 publication Critical patent/MA32557B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un modulateur du récepteur de s1p représenté par la formule (ia) ou (ib), la signification des différents résidus étant celle qui est indiquée dans la revendication 1, dans la préparation d'un médicament servant à la prophylaxie, à l'inhibition ou au traitement d'un état inflammatoire sélectionné dans des maladies telles que la polymyosite, la dermatomyosite ou des maladies musculo-nerveuses, telles que des dystrophies musculaires ou la myosite à corps d'inclusion.
MA33608A 2008-07-23 2011-02-11 Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire MA32557B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161005 2008-07-23
PCT/EP2009/059440 WO2010010127A1 (fr) 2008-07-23 2009-07-22 Modulateurs du récepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire

Publications (1)

Publication Number Publication Date
MA32557B1 true MA32557B1 (fr) 2011-08-01

Family

ID=40090418

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33608A MA32557B1 (fr) 2008-07-23 2011-02-11 Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire

Country Status (25)

Country Link
US (2) US9149459B2 (fr)
EP (2) EP2695615A3 (fr)
JP (2) JP5878015B2 (fr)
KR (2) KR101624098B1 (fr)
CN (1) CN102105144B (fr)
AU (1) AU2009273259B2 (fr)
BR (1) BRPI0916232A2 (fr)
CA (1) CA2730751A1 (fr)
CL (1) CL2011000138A1 (fr)
CY (1) CY1115662T1 (fr)
DK (1) DK2307007T3 (fr)
ES (1) ES2522345T3 (fr)
HK (1) HK1155096A1 (fr)
HR (1) HRP20141152T1 (fr)
IL (2) IL210550A (fr)
MA (1) MA32557B1 (fr)
MX (1) MX2011000881A (fr)
NZ (1) NZ590328A (fr)
PL (1) PL2307007T3 (fr)
PT (1) PT2307007E (fr)
RU (1) RU2521286C2 (fr)
SG (1) SG10201503157PA (fr)
SI (1) SI2307007T1 (fr)
WO (1) WO2010010127A1 (fr)
ZA (1) ZA201100166B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186473B (zh) * 2008-08-18 2014-07-02 诺华股份有限公司 用于治疗周围神经病的化合物
WO2012097330A2 (fr) * 2011-01-14 2012-07-19 University Of Washington Compositions et méthodes de traitement d'affections musculaires dégénératives
FR3000959B1 (fr) 2013-01-14 2015-08-21 Holis Technologies Nouveaux intermediaires de synthese permettant d'acceder avec de bons rendements a des derives de sphingosines, ceramides et sphingomyelines
CA2973540A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant
EP3311161B1 (fr) 2015-06-18 2021-04-21 Cytoo Procédé de criblage fonctionnel et à débit élevé de troubles apparentés musculaires et de processus biologiques
EP3400211A1 (fr) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Modulateurs azétidine du récepteur de la sphingosine 1-phosphate
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US20230295076A1 (en) * 2020-08-20 2023-09-21 Medshine Discovery Inc. Acetophenone oxime compound and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749419B1 (fr) * 1994-03-10 2001-10-24 Bayer Ag Derives d'oxime et leur utilisation comme pesticides
AR035411A1 (es) 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
WO2003005965A2 (fr) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulateurs de ceramidase et procedes d'utilisation associes
JP4430941B2 (ja) * 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
AU2003216054B2 (en) * 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
TW200424187A (en) * 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
ES2379169T3 (es) * 2003-05-19 2012-04-23 Irm Llc Composiciones y compuestos inmunosupresores
TW200505442A (en) * 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2005212834A1 (en) * 2004-02-16 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (fr) 2004-05-05 2005-12-01 Adler, Richard, S. Systemes et techniques de protection d'un bateau contre des attaques en surface ou sous l'eau
WO2006047195A2 (fr) * 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
RU2478384C2 (ru) 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
MX2009001788A (es) * 2006-08-17 2009-09-23 Univ Chicago Tratamiento de enfermedades inflamatorias.
AU2007298593A1 (en) * 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
JO2686B1 (en) * 2007-04-19 2013-03-03 جلاكسو جروب ليمتد Vehicles
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
RU2561681C2 (ru) 2008-12-22 2015-08-27 Новартис Аг Схема приема агониста рецептора s1p

Also Published As

Publication number Publication date
NZ590328A (en) 2013-04-26
KR20160039694A (ko) 2016-04-11
PT2307007E (pt) 2014-11-13
ES2522345T3 (es) 2014-11-14
SG10201503157PA (en) 2015-06-29
WO2010010127A1 (fr) 2010-01-28
JP2011528695A (ja) 2011-11-24
HK1155096A1 (en) 2012-05-11
CN102105144A (zh) 2011-06-22
EP2695615A2 (fr) 2014-02-12
JP2015038100A (ja) 2015-02-26
SI2307007T1 (sl) 2014-11-28
IL210550A0 (en) 2011-03-31
US20160175282A1 (en) 2016-06-23
HRP20141152T1 (hr) 2015-01-16
ZA201100166B (en) 2011-09-28
RU2011106356A (ru) 2012-08-27
US9149459B2 (en) 2015-10-06
MX2011000881A (es) 2011-03-02
PL2307007T3 (pl) 2015-03-31
JP5878015B2 (ja) 2016-03-08
CL2011000138A1 (es) 2011-07-01
KR101624098B1 (ko) 2016-05-24
RU2521286C2 (ru) 2014-06-27
IL243612A0 (en) 2016-02-29
US20110124620A1 (en) 2011-05-26
EP2695615A3 (fr) 2014-04-30
KR20110031996A (ko) 2011-03-29
KR101608108B1 (ko) 2016-03-31
BRPI0916232A2 (pt) 2017-08-29
EP2307007B1 (fr) 2014-08-27
IL210550A (en) 2016-02-29
CY1115662T1 (el) 2017-01-25
CA2730751A1 (fr) 2010-01-28
AU2009273259A1 (en) 2010-01-28
AU2009273259B2 (en) 2013-05-02
DK2307007T3 (da) 2014-11-10
EP2307007A1 (fr) 2011-04-13
CN102105144B (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
MA32557B1 (fr) Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire
PH12014501560A1 (en) Carbamate compounds and of making and using same
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
WO2009137217A8 (fr) Régénération et enrichissement thérapeutiques de la lubrification de la surface oculaire
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
HK1142062A1 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MX2014002460A (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ626973A (en) Heterocyclic compounds and methods for their use
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
WO2014130691A3 (fr) Formulations pharmaceutiques de nitrite et leurs utilisations
WO2014110353A8 (fr) Substrats biocompatibles liés à un ligand de notch et leur utilisation dans la formation osseuse
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TW200833710A (en) Treatment for spinal muscular atrophy